REFERENCE FILE
Retatrutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Investigational
- Evidence category
- Randomized evidence
- Mechanism
- Activates GIP, GLP-1 and glucagon receptors.
- Evidence
- A randomized obesity trial was funded by Lilly.
- Limitations
- Trial averages do not predict an individual outcome.
- Safety
- The trial reported gastrointestinal adverse events.
- Formulation and route
- Studied as a subcutaneous injection.
- Approval scope
- Investigational; no FDA-approved product.
A SECOND LOOK
A question to carry into the reading
Make an identity card for the material described in a retatrutide claim. Copy the source's description of its formulation and presentation into one column, then place the wording of the claim in another. Underline only the details that match explicitly. Put unspecified details in a third column instead of completing them from a familiar name or image. Now ask whether the conclusion belongs to the described material or has been extended to a broader category. The practical result is a short list of identity questions that must be answered before you can decide whether the source and the claim concern the same thing.
Questions to keep beside the page
- Which formulation and presentation details does the source explicitly identify?
- Which details in the claim match, differ, or remain unspecified?
- What record would establish whether both descriptions refer to the same material?
Sources for this file
- FDA GLP-1FDA · Checked
- JastreboffPubMed · Checked
FROM THE REFERENCE DESK